Skip to main content

Peer Review reports

From: Anti-tumor effects of rivoceranib against canine melanoma and mammary gland tumour in vitro and in vivo mouse xenograft models

Original Submission
18 Jan 2021 Submitted Original manuscript
21 Jan 2021 Author responded Author comments - Woo-Jin Song
8 Feb 2021 Reviewed Reviewer Report
8 Feb 2021 Reviewed Reviewer Report
18 Feb 2021 Reviewed Reviewer Report
5 Apr 2021 Author responded Author comments - Woo-Jin Song
Resubmission - Version 2
21 Jan 2021 Submitted Manuscript version 2
21 Apr 2021 Author responded Author comments - Woo-Jin Song
Resubmission - Version 3
21 Apr 2021 Submitted Manuscript version 3
24 Apr 2021 Author responded Author comments - Woo-Jin Song
Resubmission - Version 4
24 Apr 2021 Submitted Manuscript version 4
12 May 2021 Reviewed Reviewer Report
18 May 2021 Reviewed Reviewer Report
31 May 2021 Reviewed Reviewer Report
10 Jul 2021 Author responded Author comments - Woo-Jin Song
Resubmission - Version 5
10 Jul 2021 Submitted Manuscript version 5
14 Jul 2021 Author responded Author comments - Woo-Jin Song
Resubmission - Version 6
14 Jul 2021 Submitted Manuscript version 6
15 Jul 2021 Author responded Author comments - Woo-Jin Song
Resubmission - Version 7
15 Jul 2021 Submitted Manuscript version 7
3 Aug 2021 Reviewed Reviewer Report
11 Aug 2021 Reviewed Reviewer Report
Resubmission - Version 8
Submitted Manuscript version 8
Publishing
7 Sep 2021 Editorially accepted
26 Oct 2021 Article published 10.1186/s12917-021-03026-1

You can find further information about peer review here.

Back to article page